Preclinical antitumor activity of novel small molecule glutaminase inhibitors in triple-negative breast cancer.

被引：0
|
作者：
Demo, Susan [1 ]
Chernov-Rogan, Tania [1 ]
Gross, Matthew [1 ]
Janes, Julie [1 ]
Kawas, Raja [1 ]
Lewis, Evan [1 ]
Parlati, Francesco [1 ]
Rodriguez, Hector [1 ]
Rodriguez, Mirna [1 ]
Yang, Jinfu [1 ]
Zhao, Frances [1 ]
Richardson, Adam [2 ]
Bennett, Mark K. [1 ]
机构：
[1] Calithera Biosci Inc, San Francisco, CA USA
[2] Sanford Burnham Med Res Inst, La Jolla, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-5604
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5604
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Antitumor activity of the glutaminase inhibitor, CB-839, in triple-negative breast cancer
    Gross, M.
    Budczies, J.
    Demo, S.
    Janes, J.
    Lewis, E.
    Parlati, F.
    MacKinnon, A.
    Rodriguez, M.
    Yang, J.
    Zhao, F.
    Richardson, A.
    Denkert, C.
    Fiehn, O.
    Bennett, M.
    CANCER RESEARCH, 2013, 73
  • [2] Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
    Gross, Matt I.
    Demo, Susan D.
    Dennison, Jennifer B.
    Chen, Lijing
    Chernov-Rogan, Tania
    Goyal, Bindu
    Janes, Julie R.
    Laidig, Guy J.
    Lewis, Evan R.
    Li, Jim
    MacKinnon, Andrew L.
    Parlati, Francesco
    Rodriguez, Mirna L. M.
    Shwonek, Peter J.
    Sjogren, Eric B.
    Stanton, Timothy F.
    Wang, Taotao
    Yang, Jinfu
    Zhao, Frances
    Bennett, Mark K.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (04) : 890 - 901
  • [3] Preclinical studies with neratinib in triple-negative breast cancer.
    Mulloly, Maeve
    O'Brien, Neil A.
    Conklin, Dylan
    Finn, Richard S.
    Slamon, Dennis J.
    Crown, John
    O'Donovan, Norma
    McGowan, Patricia M.
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Preclinical Efficacy of the Combination of Met and Src Family Kinase Inhibitors in Triple-Negative Breast Cancer.
    Gartner, E. M.
    Kim, E. M. H.
    Choi, L.
    Boerner, J.
    CANCER RESEARCH, 2011, 71
  • [5] Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer
    Zhou, Wu-Xi
    Chen, Chen
    Liu, Xiao-Qin
    Li, Ying
    Lin, Yao-Lan
    Wu, Xiu-Tao
    Kong, Ling-Yi
    Luo, Jian-Guang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 210
  • [6] Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer.
    Bevill, Samantha M.
    Sciaky, Noah
    Golitz, Brian T.
    Rashid, Naim U.
    Zawistowski, Jon S.
    Johnson, Gary L.
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 80 - 80
  • [7] Comprehensive kinome activity mapping of triple-negative breast cancer.
    Koemans, Nina M.
    Van der Borden, Carolien L.
    Mori, Miki
    Pan, Bo
    Wang, Changjun
    Van 't Veer, Laura J.
    Coppe, Jean-Philippe
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 44 - 44
  • [8] Expression of novel immunotherapeutic targets in triple-negative breast cancer.
    Basu, Gargi Dan
    Ghazalpour, Anatole
    Gatalica, Zoran
    Anderson, Karen S.
    McCullough, Ann E.
    Spetzer, David B.
    Pockaj, Barbara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Discovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer
    Luo, Ran
    Zhao, Haoyi
    Deng, Siqi
    Wu, Jiale
    Wang, Haijun
    Guo, Xiaoshan
    Han, Cuicui
    Ren, Wenkang
    Han, Yinglong
    Zhou, Jianwen
    Lin, Yu
    Bu, Ming
    MOLECULES, 2024, 29 (18):
  • [10] Discovery of a small molecule inhibitor for triple-negative breast cancer (TNBC)
    Saran, Uttara
    Chandrasekaran, Balaji
    Tyagi, Ashish
    Singh, Amandeep
    Ankem, Murali K.
    Sharma, Arun K.
    Damodaran, Chendil
    CANCER RESEARCH, 2022, 82 (12)
12345